Compare Charles River Laboratories Intl. Inc (CRL) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Gartner Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B), while Gartner Inc trades at $132.89 (market cap $8.90B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| CRL | IT | |
|---|---|---|
Market Cap | $11.14B | $8.90B |
Sector | Health | Technology |
52-Week High | $233.60 | $363.58 |
52-Week Low | $145.57 | $125.68 |
Enterprise Value | $14.00B | $10.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Gartner (IT) trades at $141.31, up 6.06% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729 million. Recent news highlights its leadership in AI platforms, but an ongoing legal investigation poses a near-term risk.
Outlook remains positive with a consensus price target of $157.60, suggesting 11.5% upside. Key opportunities include sustained demand for IT research and consulting, while risks involve heightened competition and the February 2025 legal probe. Institutional sentiment is mixed with 27.8% buy ratings amid cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
